[MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection]

Rinsho Ketsueki. 2018;59(3):315-322. doi: 10.11406/rinketsu.59.315.
[Article in Japanese]

Abstract

An 18-year-old man was diagnosed with Epstein-Barr virus (EBV) -associated hemophagocytic syndrome (HPS) and treated with prednisolone (PSL) at a previous hospital. During PSL tapering, the HPS symptoms reappeared, and the patient was referred to our hospital. Increased PSL improved the symptoms, but the EBV infection remained unresolved. At age 20, he was admitted to our hospital for newly developed pneumonia and diagnosed with myelodysplastic syndrome (refractory cytopenia with multilineage dysplasia) (MDS-RCMD; normal karyotype, IPSS: Int-1) by bone marrow examination. MDS remission was achieved following bone marrow transplantation from an unrelated donor, and he is currently alive without relapse. The patient's father had also been diagnosed with MDS when he was young and died from leukoencephalopathy at approximately 50 years old. These observations support a diagnosis of familial MDS. GATA2 mutation p.R230Hfs*44 was identified in both bone marrow and control cells (buccal swab) at MDS diagnosis, and he was diagnosed with monocytopenia and mycobacterial infection (MonoMAC) syndrome. Furthermore, an acquired STAG2 mutation (splicing site change, c.820-2A>G) in the bone marrow cells was also identified, which might contribute to MDS progression.

Keywords: GATA2 mutation; MDS; MonoMAC syndrome; STAG2 mutation.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Bone Marrow
  • Bone Marrow Transplantation
  • DNA Mutational Analysis
  • Epstein-Barr Virus Infections / complications*
  • GATA2 Deficiency / complications*
  • GATA2 Transcription Factor / genetics
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / etiology*
  • Myelodysplastic Syndromes / therapy
  • Remission Induction
  • Young Adult

Substances

  • GATA2 Transcription Factor
  • GATA2 protein, human